Taysha Gene Therapies (TSHA)
NASDAQ:TSHA

Taysha Gene Therapies Stock Analysis & Ratings

TSHA Stock Chart & Stats

Day’s Range$2.81 - $3.14
52-Week Range$2.69 - $26.99
Previous Close$2.98
Volume119.83K
Average Volume (3M)262.12K
Market Cap$115.56M
P/E Ratio-0.6
Beta2.24
Next EarningsAug 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8
EPS (TTM)-5.07


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

TSHA FAQ

What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $2.69 and its highest was $26.99 in the past 12 months.
    What is Taysha Gene Therapies’s market cap?
    Taysha Gene Therapies’s market cap is $115.56M.
      What is Taysha Gene Therapies’s price target?
      The average price target for Taysha Gene Therapies is $28.33. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $37.00 ,the lowest forecast is $20.00. The average price target represents 894.04% Increase from the current price of $2.85.
        What do analysts say about Taysha Gene Therapies?
        Taysha Gene Therapies’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
          When is Taysha Gene Therapies’s upcoming earnings report date?
          Taysha Gene Therapies’s upcoming earnings report date is Aug 15, 2022 which is in 87 days.
            How were Taysha Gene Therapies’s earnings last quarter?
            Currently, no data Available
            Is Taysha Gene Therapies overvalued?
            According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
              Does Taysha Gene Therapies pay dividends?
              Taysha Gene Therapies does not currently pay dividends.
              What is Taysha Gene Therapies’s EPS estimate?
              Taysha Gene Therapies’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Taysha Gene Therapies have?
              Taysha Gene Therapies has 40,550,000 shares outstanding.
                What happened to Taysha Gene Therapies’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of Taysha Gene Therapies?
                Among the largest hedge funds holding Taysha Gene Therapies’s share is Perceptive Advisors LLC. It holds Taysha Gene Therapies’s shares valued at N/A.

                  ---

                  Taysha Gene Therapies Stock Analysis

                  Smart Score
                  8
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  Price Target
                  $28.33
                  ▲(894.04% Upside)
                  Strong Buy
                  The Taysha Gene Therapies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Taysha Gene Therapies

                  Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

                  ---
                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis